$NMRA
Neumora Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024054448 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.19M $14.32M $9.680M
YoY Change 63.55% 47.9% 19.65%
% of Gross Profit
Research & Development $48.63M $45.76M $29.49M
YoY Change 48.39% 55.16% 33.14%
% of Gross Profit
Depreciation & Amortization $160.0K $158.0K $160.0K
YoY Change -5.88% -1.25% 6.67%
% of Gross Profit
Operating Expenses $63.82M $60.07M $39.17M
YoY Change 51.74% 53.37% 29.53%
Operating Profit -$63.82M -$60.07M -$39.17M
YoY Change 51.73% 53.38%
Interest Expense $5.271M $6.365M $3.570M
YoY Change 48.06% 78.29% 3866.67%
% of Operating Profit
Other Income/Expense, Net $5.247M $6.353M -$30.00K
YoY Change -13217.5% -21276.67% -127.27%
Pretax Income -$58.58M -$53.72M -$35.63M
YoY Change 51.98% 50.77% -17.22%
Income Tax $125.0K
% Of Pretax Income
Net Earnings -$58.70M -$53.72M -$35.63M
YoY Change 52.3% 50.8% -17.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37 -$0.34 -$1.22
Diluted Earnings Per Share -$0.37 -$0.34 -$0.23
COMMON SHARES
Basic Shares Outstanding 159.5M 158.9M 29.28M
Diluted Shares Outstanding 159.0M 157.9M 29.28M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $371.6M $422.7M $345.5M
YoY Change 14.63% 22.35% -1.17%
Cash & Equivalents $150.7M $182.9M $210.9M
Short-Term Investments $221.0M $239.8M $134.7M
Other Short-Term Assets $25.05M $19.16M $13.60M
YoY Change 112.28% 40.91% 3.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables $1.631M $906.0K
Total Short-Term Assets $398.3M $442.8M $360.0M
YoY Change 18.34% 23.0% -0.8%
LONG-TERM ASSETS
Property, Plant & Equipment $1.476M $1.635M $9.700M
YoY Change -83.03% -83.14% 155.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $302.0K $18.30M
YoY Change -100.0% -98.35% 32.61%
Other Assets $1.213M $1.213M $4.100M
YoY Change -74.73% -70.41% 78.26%
Total Long-Term Assets $6.154M $7.426M $32.10M
YoY Change -73.7% -76.87% 61.31%
TOTAL ASSETS
Total Short-Term Assets $398.3M $442.8M $360.0M
Total Long-Term Assets $6.154M $7.426M $32.10M
Total Assets $404.5M $450.2M $392.1M
YoY Change 12.35% 14.82% 2.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.082M $1.492M $1.100M
YoY Change -86.8% 35.64% -31.25%
Accrued Expenses $18.30M $19.49M $20.40M
YoY Change 2.83% -4.45% 31.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.13M $24.61M $21.80M
YoY Change -11.4% 12.89% 21.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $89.00K $1.060M $4.500M
YoY Change -97.59% -76.44% 309.09%
Total Long-Term Liabilities $89.00K $1.060M $4.500M
YoY Change -97.59% -76.44% 309.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.13M $24.61M $21.80M
Total Long-Term Liabilities $89.00K $1.060M $4.500M
Total Liabilities $23.21M $25.67M $26.30M
YoY Change -22.1% -2.4% 38.42%
SHAREHOLDERS EQUITY
Retained Earnings -$815.9M -$757.2M
YoY Change
Common Stock $1.197B $1.182B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $381.3M $424.5M -$477.9M
YoY Change
Total Liabilities & Shareholders Equity $404.5M $450.2M $392.1M
YoY Change 12.35% 14.82% 2.43%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$58.70M -$53.72M -$35.63M
YoY Change 52.3% 50.8% -17.23%
Depreciation, Depletion And Amortization $160.0K $158.0K $160.0K
YoY Change -5.88% -1.25% 6.67%
Cash From Operating Activities -$56.16M -$42.96M -$33.04M
YoY Change 81.04% 30.01% 2.64%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $775.0K $40.00K
YoY Change 1837.5% -99.7%
Acquisitions
YoY Change
Other Investing Activities $21.25M -$149.2M $2.850M
YoY Change -11.73% -5336.0% -103.93%
Cash From Investing Activities $21.25M -$150.0M $2.820M
YoY Change -11.73% -5419.18% -103.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.654M 1.845M 100.0K
YoY Change 815.17% 1745.0% -128.57%
NET CHANGE
Cash From Operating Activities -56.16M -42.96M -33.04M
Cash From Investing Activities 21.25M -150.0M 2.820M
Cash From Financing Activities 2.654M 1.845M 100.0K
Net Change In Cash -32.25M -191.1M -30.12M
YoY Change 384.95% 534.5% -74.51%
FREE CASH FLOW
Cash From Operating Activities -$56.16M -$42.96M -$33.04M
Capital Expenditures $0.00 $775.0K $40.00K
Free Cash Flow -$56.16M -$43.73M -$33.08M
YoY Change 81.04% 32.19% -27.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001885522
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1274
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41802
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NEUMORA THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4367680
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
490 Arsenal Way
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2024Q1 dei City Area Code
CityAreaCode
857
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
760-0900
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
NMRA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
159523997
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
182927000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
374038000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
239788000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
79944000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20070000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24297000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
442785000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
478279000
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
302000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9845000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1635000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1790000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4276000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5068000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2024Q1 us-gaap Assets
Assets
450211000
CY2023Q4 us-gaap Assets
Assets
496195000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1492000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
337000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19493000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21257000
CY2024Q1 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
133000
CY2023Q4 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
139000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3491000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3378000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24609000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25111000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
938000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1853000
CY2024Q1 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
122000
CY2023Q4 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
155000
CY2024Q1 us-gaap Liabilities
Liabilities
25669000
CY2023Q4 us-gaap Liabilities
Liabilities
27119000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1181829000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1172570000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-148000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-76000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-757155000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-703434000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
424542000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
469076000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
450211000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
496195000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45757000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29485000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14317000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9683000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
60074000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
39168000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-60074000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-39168000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6365000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3569000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6353000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3543000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-53721000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35625000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-72000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
476000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53793000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35149000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
157943000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
157943000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29277000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29277000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
469076000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1845000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
41000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-72000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7373000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-53721000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
424542000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-446850000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
602000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1282000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
476000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2195000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35625000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-477920000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-53721000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-35625000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7373000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2195000
CY2024Q1 nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
791000
CY2023Q1 nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
799000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
158000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
158000
CY2024Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
1147000
CY2023Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
892000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7351000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7858000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1155000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6012000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4113000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-736000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-802000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-801000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42955000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33041000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
185804000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
41483000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36578000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44336000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
CY2024Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
775000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150001000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2817000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1845000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
602000
CY2023Q1 nmra Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
491000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1845000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-191111000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30123000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
375251000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242206000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
184140000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
212083000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
182927000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
210870000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
1213000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1213000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
184140000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
212083000
CY2024Q1 nmra Number Of Clinical And Preclinical Neuroscience Programs
NumberOfClinicalAndPreclinicalNeurosciencePrograms
7
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
7.8463-for-1
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair value of the Company’s convertible preferred stock, the fair value of the Company’s common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company’s estimates.</span></p>
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
383055000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
9000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
157000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
382907000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
452119000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
26000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
102000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
452043000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2024Q1 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
5923000
CY2023Q4 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
4705000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
542000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
750000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
239788000
CY2024Q1 nmra Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
302000
CY2024Q1 nmra Estimated Fair Value Of Available For Sale Debt Securities Fair Value
EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue
240090000
CY2024Q1 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
1
CY2024Q1 nmra Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
14603000
CY2023Q4 nmra Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
19085000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4561000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4273000
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
906000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
939000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20070000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24297000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4660000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10011000
CY2024Q1 nmra Accrued Research And Development Services Due To Related Party
AccruedResearchAndDevelopmentServicesDueToRelatedParty
6300000
CY2023Q4 nmra Accrued Research And Development Services Due To Related Party
AccruedResearchAndDevelopmentServicesDueToRelatedParty
3100000
CY2024Q1 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
7442000
CY2023Q4 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
5004000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
926000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19493000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21257000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
37049000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7373000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2195000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-53721000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35625000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
157943000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
157943000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29277000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29277000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18044000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
117434000

Files In Submission

Name View Source Status
0000950170-24-054448-index-headers.html Edgar Link pending
0000950170-24-054448-index.html Edgar Link pending
0000950170-24-054448.txt Edgar Link pending
0000950170-24-054448-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img235846496_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nmra-20240331.htm Edgar Link pending
nmra-20240331.xsd Edgar Link pending
nmra-ex10_1.htm Edgar Link pending
nmra-ex10_2.htm Edgar Link pending
nmra-ex31_1.htm Edgar Link pending
nmra-ex31_2.htm Edgar Link pending
nmra-ex32_1.htm Edgar Link pending
nmra-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nmra-20240331_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending